Allspring Global Investments Holdings LLC Buys 7,463 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Allspring Global Investments Holdings LLC boosted its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 3.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 252,602 shares of the biotechnology company’s stock after acquiring an additional 7,463 shares during the period. Allspring Global Investments Holdings LLC owned 0.11% of ADMA Biologics worth $1,667,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in ADMA. AJOVista LLC bought a new stake in ADMA Biologics in the fourth quarter worth about $77,000. Oxford Asset Management LLP bought a new stake in shares of ADMA Biologics in the fourth quarter valued at approximately $83,000. Viewpoint Capital Management LLC raised its position in shares of ADMA Biologics by 18.6% in the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 2,416 shares during the period. Intrust Bank NA raised its position in shares of ADMA Biologics by 70.2% in the fourth quarter. Intrust Bank NA now owns 24,221 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 9,992 shares during the period. Finally, Bailard Inc. bought a new stake in shares of ADMA Biologics in the fourth quarter valued at approximately $110,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $11.21 on Thursday. The firm’s 50 day simple moving average is $9.41 and its 200 day simple moving average is $6.86. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91. The firm has a market capitalization of $2.60 billion, a PE ratio of -560.50 and a beta of 0.54. ADMA Biologics, Inc. has a 1-year low of $3.06 and a 1-year high of $11.68.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.03. The business had revenue of $81.90 million for the quarter, compared to analyst estimates of $77.28 million. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. ADMA Biologics’s revenue was up 43.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.03) EPS. As a group, analysts expect that ADMA Biologics, Inc. will post 0.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ADMA Biologics news, CEO Adam S. Grossman sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $10.72, for a total value of $1,072,000.00. Following the completion of the transaction, the chief executive officer now owns 2,081,475 shares of the company’s stock, valued at approximately $22,313,412. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 3.70% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. HC Wainwright boosted their price target on shares of ADMA Biologics from $7.50 to $10.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Mizuho boosted their price target on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. Cantor Fitzgerald boosted their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Friday, May 10th. Finally, Raymond James upped their target price on shares of ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong-buy” rating in a report on Friday, May 10th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $11.00.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.